Ribometrix
Caleb D. Sutherland, Ph.D. began their career in 2003 as a Material Handler and Dangerous Goods Specialist at FedEx Express. In 2010, they began their Ph.D. Graduate Student studies at the University of Arizona, and in 2012 they took on an Adjunct Faculty role at Pima Community College. In 2015, they became a Postdoctoral Fellow at the National Institute of Environmental Health Sciences (NIEHS), where they studied a family of proteins known as GLIS1, GLIS2, and GLIS3, in order to better understand cellular processes involving these proteins and provide future strategies to treat Polycystic Kidney Disease (PKD) and glaucoma. In 2018, they joined Ribometrix Inc. as a Senior Scientist, Scientist - Molecular and Cell Biology, and Scientist II - RNA Biology.
Caleb D. Sutherland, Ph.D. began their educational journey at Capital High School in Boise, Idaho from 1999-2003. Caleb D. then attended Boise State University from 2004-2010, where they earned a Bachelor's Degree in Cell/Cellular and Molecular Biology. Finally, they attended the University of Arizona from 2010-2015 and earned a Doctor of Philosophy (Ph.D.) in Cancer Biology and Pharmacology.
Ribometrix
Ribometrix, headquartered in Durham, North Carolina, is a biotechnology company leveraging world-leading expertise in three-dimensional structural analysis of RNA as the foundation of its proprietary drug discovery platform. This platform enables the identification of novel small molecules that modulate the function of RNA and proteins associated with human disease. Ribometrix’ value creation strategy is built around developing an internal pipeline of drug candidates and partnerships with the leading biopharmaceutical companies. Ribometrix is backed by a syndicate of blue-chip venture investors.